Branham Law, LLP Announces An Investigation Of Chelsea Therapeutics International, Ltd. For Possible Securities Law Violations

Branham Law, LLP announces an investigation has been launched into the actions of the officers and directors of Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) (“Chelsea” or the “Company”) for possible violations of securities and shareholder protection laws.

If you purchased shares of Chelsea between November 3, 2008 and March 28, 2012 or have relevant information regarding this suit, you are urged to contact attorney Trey Branham at tbranham@branham-law.com or toll free at (855) 722-5910.

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) Chelsea’s Northera (droxidopa) product, an orally-active synthetic precursor of norepinephrine being developed for the treatment of symptomatic neurogenic orthostatic hypotension, would not receive approval from the U.S. Food and Drug Administration; and (2) the Company’s numerous statements regarding the safety and efficacy of the product, as well as reportedly positive results from Northera’s clinical trials, were materially false and misleading.

Branham Law, LLP has significant experience in shareholder representation nationwide.

Copyright Business Wire 2010